HCQ and Covid Pathology
COVID19 - CORONAVIRUS, 31 Aug 2020
26 Aug 2020 – In recent weeks, several more prospective and retrospective studies have confirmed the effectiveness of malaria drug HCQ against covid-19, both in primary care and in hospitals, and both in the general population and in nursing homes. The studies typically found risk reductions between 30% and 50% (e.g. reduced hospitalizations, disease duration or mortality).
At this point it is rather obvious that Western health authorities falsely discarded HCQ based on the fraudulent Surgisphere “study” (using fake data) and the misdesigned WHO trials (using lethal doses in late-stage disease), while pushing much more expensive and risky drugs. As a former French health minister explained in May, where some see disease, others see dollars.
Meanwhile, German pathologists found that the risk of lung microthrombosis in severe covid is about nine times higher compared to influenza (English video). They also found that the new coronavirus can use not only the ACE2 receptor, but also the NRP1 receptor, which explains the frequent olfactory symptoms (viz. the temporary loss of the sense of taste or smell).
Given what we now know about severe covid, but also about widespread post-acute “long covid” in younger and previously healthy people, health authorities should seriously consider large-scale prophylactic and early treatment based on simple, safe and effective means.
Tags: Airborne contagion, Brain, COVID-19, China, Community, Compassion, Coronavirus, Cuba, Economy, Empathy, Environment, Health, Lockdown, Orthomolecular Medicine, Pandemic, Public Health, Research, Science, Science and Medicine, Semen, Sharing, Sperm, Swiss Policy Research, Trade, United Nations, WHO, World
DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.
Click here to go to the current weekly digest or pick another article:
COVID19 - CORONAVIRUS: